GlaxoSmithKline
GSK paves way for biopharmaceuticals growth
September 9, 2010Research and Development GlaxoSmithKline, Lonza, biologics
GlaxoSmithKline has handed Swiss contract manufacturer Lonza a contract to produce clinical trial batches of five monoclonal antibodies that are …
Pressure mounts on GSK over Avandia
September 6, 2010Sales and Marketing Avandia, GlaxoSmithKline
GlaxoSmithKline is under mounting pressure this week as calls intensify for its type II diabetes drug Avandia to be withdrawn …
EMA to assess GSK flu vaccine for narcolepsy link
September 1, 2010Research and Development, Sales and Marketing GlaxoSmithKline, Pandemrix, h1n1
The European Medicines Agency has launched a review of GlaxoSmithKline’s influenza vaccine Pandemrix. The European Commission asked the EMA to …
A revolution for the NHS – an opportunity for pharma?
August 9, 2010Sales and Marketing GlaxoSmithKline, NHS
Healthcare systems across western Europe are currently under renewed pressure and scrutiny, each government preoccupied with finding major cost-savings to …
GSK’s Arixtra set for expanded licence
July 26, 2010Sales and Marketing Arixtra, Avandia, GlaxoSmithKline, rotarix
GlaxoSmithKline is set to receive a green light to use its anti-clotting drug Arixtra to prevent spontaneous superficial-vein thrombosis (SVT). …
Legal costs dent GlaxoSmithKline’s Q2
July 22, 2010Medical Communications, Sales and Marketing 2010 financials, GlaxoSmithKline, Q2
GSK has reported a loss for its second quarter due to litigation costs related to Avandia and other problems. In …
GSK takes £1.58bn hit from legal disputes
July 16, 2010Sales and Marketing Avandia, GlaxoSmithKline, Paxcil, Seroxat
GlaxoSmithKline is set to pay £1.58 billion to settle three long-standing legal disputes, including litigation costs for its troubled diabetes …
GSK accused of Avandia cover-up
July 14, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
The ongoing battle over GlaxoSmithKline’s diabetes drug Avandia has taken another turn with US senators accusing the company of a …
Avandia to face European safety review
July 12, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline’s type II diabetes drug Avandia, the subject of safety concerns since its launch in 2000, is to be reviewed …
Aptuit deal saves GSK’s R&D unit in Verona
July 5, 2010Manufacturing and Production, Research and Development Aptuit, GlaxoSmithKline, Italy
GlaxoSmithKline has sold off its medicines research facility in Verona, Italy, to contract research and manufacturing service group Aptuit in …
Duncan Learmouth to lead new GSK unit
July 5, 2010Sales and Marketing GlaxoSmithKline, appointment, em, market access, sales and marketing
GlaxoSmithKline has created a new business group dedicated to improving access to medicines in the world’s least developed countries. GSK’s …
Avandia probe deepens
June 29, 2010Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline has come under further scrutiny from the FDA after two new studies showed patients taking its troubled diabetes medication …
Prosensa and GSK add to muscular dystrophy alliance
June 23, 2010Research and Development GlaxoSmithKline, Prosensa, muscular dystrophy
GSK has extended its research alliance with biotech company Prosensa in the field of muscular dystrophy. Netherlands-based Prosensa focuses on …
GSK tops access to medicines ranking
June 21, 2010Sales and Marketing GlaxoSmithKline, developing world, medicines access
GlaxoSmithKline does the most of any pharma manufacturer to improve access to medicines needed in the developing world, according to …
GSK’s Votrient approved in Europe
June 16, 2010Sales and Marketing GlaxoSmithKline, Kidney cancer, Votrient
The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of …
Latest content
